Form 4: Sana Biotechnology Director Receives Stock Option Grant

Director Alise Reicin was granted 90,000 stock options in Sana Biotechnology, Inc. as part of standard equity compensation.

Summary

• Director Alise Reicin received a grant of 90,000 stock options on June 4, 2026.
• The options have an exercise price of $2.96 per share.
• The options are set to vest in full on the earlier of June 4, 2027, or the date of the 2027 annual meeting of stockholders.
• The expiration date for these options is June 3, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the underlying common stock.
• The requirement for continuous service to the company to achieve full vesting of the options.

Future Outlook

The options vest in one year, contingent upon the director's continued service to the company through the vesting date.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to attract and retain high-level expertise for oversight and strategic guidance.

Comparison to Industry Standards

• The grant size and vesting schedule are consistent with typical director compensation packages for mid-cap biotechnology firms.
• The use of a one-year cliff vesting period is a common industry standard for board-level equity awards.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of the 90,000 stock options on June 4, 2027.

Key Dates

Keywords

Sana Biotechnology, SANA, Director Compensation, Stock Options, SEC Form 4, Equity Grant